Molecular Medicine

, Volume 21, Issue 1, pp 296–304 | Cite as

miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity

  • Christiane Gras
  • Dominica Ratuszny
  • Catarina Hadamitzky
  • Haijiao Zhang
  • Rainer Blasczyk
  • Constança Figueiredo
Research Article


Hyperthrophic scarring of the skin is caused by excessive activity of skin myofibroblasts after wound healing and often leads to functional and/or aesthetic disturbance with significant impairment of patient quality of life. MicroRNA (miRNA) gene therapies have recently been proposed for complex processes such as fibrosis and scarring. In this study, we focused on the role of miR-145 in skin scarring and its influence in myofibroblast function. Our data showed not only a threefold increase of miR-145 levels in skin hypertrophic scar tissue but also in transforming growth factor β1 (TGF-β1)-induced skin myofibroblasts compared with healthy skin or nontreated fibroblasts (p < 0.001). Consistent with the upregulation of miR-145 induced by TGF-β1 stimulation of fibroblasts, the expression of Kruppel-like factor 4 (KLF4) was decreased by 50% and α-smooth muscle actin (α-SMA) protein expression showed a threefold increase. Both could be reversed by miR-145 inhibition (p < 0.05). Restoration of KLF4 levels equally abrogated TGF-β1-induced α-SMA expression. These data demonstrate that TGF-β1 induces miR-145 expression in fibroblasts, which in turn inhibits KLF4, a known inhibitor of α-SMA, hence upregulating α-SMA expression. Furthermore, treatment of myofibroblasts with a miR-145 inhibitor strongly decreased their α-1 type I collagen expression, TGF-β1 secretion, contractile force generation and migration. These data demonstrate that upregulation of miR-145 plays an important role in the differentiation and function of skin myofibroblasts. Additionally, inhibition of miR-145 significantly reduces skin myofibroblast activity. Taken together, these results suggest that miR-145 is a promising therapeutic target to prevent or reduce hypertrophic scarring of the skin.



We are grateful to Stefanie Vahlsing for technical assistance. This work was supported in part by funding from the German Research Foundation (DFG) for the Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy) (EXC 62) (to C Gras and C Figueiredo).


  1. 1.
    Kathju S, Gallo PH, Satish L. (2012) Scarless integumentary wound healing in the mammalian fetus: molecular basis and therapeutic implications. Birth Defects Res. C. Embryo Today. 96:223–36.CrossRefGoogle Scholar
  2. 2.
    Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A. (2008) The hidden cost of skin scars: quality of life after skin scarring. J. Plast. Reconstr. Aesthet. Surg. 61:1049–58.CrossRefGoogle Scholar
  3. 3.
    Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. (2002) Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat. Rev. Mol. Cell. Biol. 3:349–63.CrossRefGoogle Scholar
  4. 4.
    Liu J, et al. (2012) Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. J. Dermatol. Sci. 65:38–49.CrossRefGoogle Scholar
  5. 5.
    Hinz B, et al. (2012) Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180:1340–55.CrossRefGoogle Scholar
  6. 6.
    Brown BD, Naldini L. (2009) Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10:578–85.CrossRefGoogle Scholar
  7. 7.
    Thomas M, Lieberman J, Lal A. (2010) Desperately seeking microRNA targets. Nat. Struct. Mol. Biol. 17:1169–74.CrossRefGoogle Scholar
  8. 8.
    Lanford RE, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 327:198–201.CrossRefGoogle Scholar
  9. 9.
    Thum T, et al. (2011) Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J. Clin. Invest. 121:461–462; author reply 462–463.CrossRefGoogle Scholar
  10. 10.
    Cheng J, Wang Y, Wang D, Wu Y. (2012) Identification of collagen 1 as a post-transcriptional target of miR-29b in skin fibroblasts: therapeutic implication for scar reduction. Am. J. Med. Sci. 346:98–103.CrossRefGoogle Scholar
  11. 11.
    Kashiyama K, et al. (2012) miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts. J. Invest. Dermatol. 132:1597–604.CrossRefGoogle Scholar
  12. 12.
    Gras C, et al. (2013) HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum. Gene Ther. 24:1018–28.CrossRefGoogle Scholar
  13. 13.
    Mia MM, Boersema M, Bank RA. (2014) Interleukin-1beta attenuates myofibroblast formation and extracellular matrix production in dermal and lung fibroblasts exposed to transforming growth factor-beta1. PLoS One. 9:e91559.CrossRefGoogle Scholar
  14. 14.
    Pan Z, et al. (2012) MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 126:840–50.CrossRefGoogle Scholar
  15. 15.
    Robinson PM, et al. (2013) MicroRNA signature in wound healing following excimer laser ablation: role of miR-133b on TGFbeta1, CTGF, SMA, and COL1A1 expression levels in rabbit corneal fibroblasts. Invest. Ophthalmol. Vis. Sci. 54:6944–51.CrossRefGoogle Scholar
  16. 16.
    Yang S, et al. (2013) miR-145 regulates myofibroblast differentiation and lung fibrosis. FASEB J. 27:2382–91.CrossRefGoogle Scholar
  17. 17.
    Wang YS, et al. (2013) Role of miR-145 in cardiac myofibroblast differentiation. J. Mol. Cell Cardiol. 66:94–105.CrossRefGoogle Scholar
  18. 18.
    Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 137:647–58.CrossRefGoogle Scholar
  19. 19.
    Davis-Dusenbery BN, et al. (2011) Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J. Biol. Chem. 286:28097–110.CrossRefGoogle Scholar
  20. 20.
    Wipff PJ, Rifkin DB, Meister JJ, Hinz B. (2007) Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 179:1311–23.CrossRefGoogle Scholar
  21. 21.
    Gurtner GC, Werner S, Barrandon Y, Longaker MT. (2008) Wound repair and regeneration. Nature. 453:314–21.CrossRefGoogle Scholar
  22. 22.
    Penn JW, Grobbelaar AO, Rolfe KJ. (2012) The role of the TGF-beta family in wound healing, burns and scarring: a review. Int. J. Burns Trauma. 2:18–28.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Cheng J, Yu H, Deng S, Shen G. (2010) MicroRNA profiling in mid- and late-gestational fetal skin: implication for scarless wound healing. Tohoku J. Exp. Med. 221:203–9.CrossRefGoogle Scholar
  24. 24.
    Li C, et al. (2013) Comparative study of microRNA profiling in keloid fibroblast and annotation of differential expressed microRNAs. Acta Biochim. Biophys. Sin. (Shanghai). 45:692–699.CrossRefGoogle Scholar
  25. 25.
    Chang HY, et al. (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 99:12877–82.CrossRefGoogle Scholar
  26. 26.
    Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. (2006) Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet. 2:e119.CrossRefGoogle Scholar
  27. 27.
    Wang R, et al. (2000) Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. 8:128–37.CrossRefGoogle Scholar
  28. 28.
    Zhao R, Yan Q, Huang H, Lv J, Ma W. (2013) Transdermal siRNA-TGFbeta1-337 patch for hypertrophic scar treatment. Matrix Biol. 32:265–76.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Christiane Gras
    • 1
  • Dominica Ratuszny
    • 1
  • Catarina Hadamitzky
    • 2
  • Haijiao Zhang
    • 1
  • Rainer Blasczyk
    • 1
  • Constança Figueiredo
    • 1
  1. 1.Hannover Medical SchoolInstitute for Transfusion MedicineHannoverGermany
  2. 2.Department of Plastic, Hand and Reconstructive SurgeryHannover Medical SchoolHannoverGermany

Personalised recommendations